Result card

  • LEG2: Are there relevant optional technologies that future patients should be allowed to consider?
English
No adaptation help available for this domain

Are there relevant optional technologies that future patients should be allowed to consider?

Authors: Marina Casini, Emanuela Midolo, Marco Marchetti

Internal reviewers: Judite Neves, Ana Bação, Vesna Kovač

The domain methodology used for this question has been collection, selection and analysis of European norms and sentences.

At present, the prognostic tests: uPA/PAI-1, MammaPrint®, and Oncotype DX® are the most advanced prognostic tests for breast cancer. Healthcare professionals are required to provide certain information and patients have a corresponding right to know what must be revealed to them and what is available. It is therefore not an omission on the part of the doctor if he/she does not provide information that they do not have and only explain what technology is being used and the possible consequences and implications for the patient. If, in the future, physicians are aware of new technological options, they are obliged to provide information about these as indicated in the documents cited in the RC-LEG1.

Important
Completely
Casini M et al. Result Card LEG2 In: Casini M et al. Legal aspects In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 2 December 2022]. Available from: http://corehta.info/ViewCover.aspx?id=113